Navigation Links
IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Date:8/27/2007

IRVINE, Calif., Aug. 27 /PRNewswire-FirstCall/ -- IDM Pharma (Nasdaq: IDMI) today announced that Jeffrey W. Sherman, M.D., F.A.C.P. has been appointed as the Company's Chief Medical Officer and Senior Vice President of Research and Development. Dr. Sherman will join the Company in September and will report to President and CEO Timothy P. Walbert.

Dr. Sherman brings close to 20 years of pharmaceutical experience to IDM Pharma and will lead the regulatory and clinical strategy for L-MTP-PE and the development of the Company's pipeline, including UVIDEM and IDM-2101. He joins IDM Pharma from Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, where he served as Vice President of Clinical Science and was focused on developing Takeda's oncology pipeline.

"Dr. Sherman's depth of oncology experience and pharmaceutical and biotechnology expertise will be an asset as we continue to work through the regulatory process with L-MTP-PE and develop our oncology pipeline," said Timothy P. Walbert, President and Chief Executive Officer of IDM Pharma, Inc. "In the near-term, Dr. Sherman will oversee the preparation and submission of the L-MTP-PE NDA amendment in the US and work closely with regulatory authorities in Europe to complete the L-MTP-PE review process."

About Dr. Jeffrey Sherman

Dr. Sherman joins IDM Pharma from Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, where he served as Vice President of Clinical Science, Oncology. Prior to Takeda, Dr. Sherman served as Chief Medical Officer and Executive Vice President at NeoPharm, Inc. where he was responsible for developing clinical drug research and development strategies.

Before joining NeoPharm, Dr. Sherman held various roles at Searle/Pharmacia Research and Development, and Medical Marketing, including Executive Director of Clinical Research and Head of Oncology Medical Operatio
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... RI (PRWEB) January 22, 2015 Protocol ... , The growing team of brand-neutral, independent consultants, Protocol ... Philip Rogers explained that over the years, his company ... , Moroso, Town of Plainfield, as well as others. ...
(Date:1/22/2015)... January 22, 2015 zFlo Motion , ... to announce an exciting product from a new partner. ... solutions over the past 15 years, with offerings in the ... their 3D IMU system (inertial measurement unit), iSen, is opening ...
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... first isolated in 2004 with the help of Scotch ... discover its potential applications. A single layer of carbon ... to flexible displays, graphene is strong, light, transparent, and ... we do with this new material? As researchers across ...
... International, Inc. (OTC Bulletin Board: MZEI ) (OTCQB: ... stock purchase agreement establishing a $10,000,000 equity line with Mammoth ... two-year term.  Under the terms of the agreement, Mammoth will ... the average closing bid price over a five day pricing ...
... 2010 GeneLink, Inc. (OTCBB: GNLK ), a leading consumer ... ended September 30, 2010. Highlights: ... Deloitte,s Technology Fast 500™ for the second year in a row ... Gary Beeman, GeneLink,s CEO stated, "The third quarter of ...
Cached Biology Technology:Doctoral candidate publishes on graphene's potential with NSF support 2Doctoral candidate publishes on graphene's potential with NSF support 3Doctoral candidate publishes on graphene's potential with NSF support 4Medizone International Secures $10,000,000 Funding Commitment 2Medizone International Secures $10,000,000 Funding Commitment 3GeneLink Reports Third Quarter Results 2
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... America Perimeter Security Systems Market" report to their offering. ... North American perimeter security market is estimated to grow at ... U.S. market holds a larger share in this market, ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today its completion ... its adherence to current U.S. Food and Drug Administration ... smart device and smart phone application trials utilizing the ... "HITLAB is determined to improve global healthcare access, ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... 2012 In a study published in the March ... Academy of Child and Adolescent Psychiatry , Katherine Rice ... of Atlanta, and Emory University School of Medicine, used ... social disability in children with autism spectrum disorders (ASD) ...
... team of researchers show that most neandertals in Europe died ... a Europe populated by a stable neandertal population for hundreds ... therefore be revised. This new perspective on the ... in Molecular Biology and Evolution . The results indicate ...
... PHOENIX, Ariz. Feb. 27, 2012 The 9th ... pancreatic cancer research at the Translational Genomics Research Institute ... will go toward new international clinical trials run by ... first time that major retailers, producers and suppliers in ...
Cached Biology News:Eye-tracking reveals variability in successful social strategies for children with autism 2European Neandertals were on the verge of extinction even before the arrival of modern humans 2Celebrity Golf Classic raises $553,443 for Seena Magowitz Foundation 2
IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
ANTI MYCOBACTERIUM TUBERCULOSIS...
ImageQuant 400, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: